DeCure for Immunodeficiency 80 with or without congenital cardiomyopathy
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for immunodeficiency 80 with or without congenital cardiomyopathy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency 80 with or without congenital cardiomyopathy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency 80 with or without congenital cardiomyopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In 141 patients with AIDS or AIDS-related complex, congestive cardiomyopathy was found in 18% (25/141). Myocarditis was suspected as the cause in 70% (14/20) of those studied. One patient with HIV-related cardiomyopathy presumed due to myocarditis developed life-threatening congestive heart failure and ventricular fibrillation, then showed clinical, echocardiographic, and electrocardiographic resolution — a unique outcome at the time. Another report describes a patient presenting with dilated cardiomyopathy during acute HIV seroconversion illness, with no opportunistic infections and a high CD4 count, suggesting HIV itself may be a direct cardiac pathogen.
A 1992 review projected that as treatment for opportunistic infections improves, the incidence of clinical cardiomyopathy in HIV-infected populations would increase. It listed HIV infection and cocaine use as examples of secondary cardiomyopathies expected to rise. The same review noted that the origins of all cardiomyopathies were not yet fully understood.
These three abstracts describe cardiomyopathy as a complication of HIV infection, not as a distinct inherited immunodeficiency. No abstract mentions a condition called immunodeficiency 80 with or without congenital cardiomyopathy. No abstract tests or proposes any drug treatment for cardiomyopathy in this context. The evidence is limited to case reports and a prevalence estimate from a single cohort.
What is missing: any controlled trial of a drug for cardiomyopathy in HIV, any genetic or molecular characterisation of the immunodeficiency described, any prospective study with predefined cardiac endpoints, and any data on patient stratification by viral load, CD4 count, or myocardial biopsy findings.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Cardiology · 1992 · 7 citations
Specific heart muscle disease
AbstractThe etiologies of all cardiomyopathies have yet to be elucidated. As new technologies are developed, the origins of various cardiomyopathies will be more clearly delineated. Human immunodeficiency virus infection and cocaine-induced cardiomyopathy are examples of secondary cardiomyopathies that are projected to increase in the near future. Our success in treating opportunistic infections that accompany the human immunodeficiency virus will contribute to an increasing incidence of clinical cardiomyopathy in the virus-infected population. This increase will require innovative diagnostics and high clinical suspicion to ameliorate debilitating myocardial dysfunction.
Clinical, Echocardiographic and Electrocardiographic Resolution of HIV-Related Cardiomyopathy
AbstractCongestive cardiomyopathy has been described in 18% (25/141) of studied patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex, and myocarditis has been suspected as the etiology in 70% (14/20) of patients studied. In previous reports the cardiomyopathy has either been asymptomatic or has been progressive and directly caused significant patient mortality and morbidity. We report a patient with human immunodeficiency virus (HIV)-related cardiomyopathy due to a presumed myocarditis which caused life-threatening congestive heart failure and ventricular fibrillation. This patient's course was unique in that she had clinical, echocardiographic, and electrocardiographic resolution of her cardiomyopathy. This report adds new knowledge to the etiology and prognosis of patients with HIV-related cardiomyopathy.
Clinical Cardiology · 1997 · 3 citations · open access
Early presentation of dilated cardiomyopathy as a part of seroconversion illness in human immunodeficiency virus infection
AbstractIt has been debated whether dilated cardiomyopathy seen in patients with acquired immune deficiency syndrome is caused by the virus itself or by the combination of other factors such as presence of opportunistic pathogens and/or severe immunosuppression. This paper describes the first reported case of a patient with human immunodeficiency virus (HIV) infection presenting with dilated cardiomyopathy during his acute seroconversion illness. Presence of cardiac involvement at a very early stage of HIV infection with no evidence of opportunistic infections, or immunosuppression with high CD4 count indicates that HIV may itself be a cardiac pathogen. This case also illustrates the importance of testing for HIV infection as part of the assessment of any patient presenting with myocarditis or dilated cardiomyopathy.
Malawi Medical Journal · 2020 · 2 citations · open access
The report of cardiomyopathy and mid aortic syndrome in a HIV infected child
AbstractCardiomyopathy is a serious complication of Human Immunodeficiency virus (HIV) infection. Direct effects of HIV, cardiac autoimmunity, opportunistic infections (OIs), nutritional deficiencies (selenium) and severe immunesuppression have been implemented for HIV related cardiomyopathy (HIVAC) ; Elevated anti-alpha myosin antibodies in HIV infection cause cardiac autoimmunity, selenium deficiency leads to cardiomyopathy, myosite invasion and cytokine release cause myocarditis whereas zidovudine triggers reversible and dose dependent myocyte toxicity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
